CRISPR Therapeutics' Julianne Bruno, M.B.A., Promoted To COO, Effective May 23, 2024
CRISPR Therapeutics' Julianne Bruno, M.B.A., Promoted To COO, Effective May 23, 2024
-Naimish Patel, M.D., appointed to Chief Medical Officer-
-醫學博士奈米什·帕特爾被任命爲首席醫療官-
-Julianne Bruno, M.B.A., promoted to Chief Operating Officer-
-工商管理碩士朱麗安·布魯諾晉升爲首席運營官-
ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company also announced the promotion of Julianne Bruno, M.B.A., to Chief Operating Officer, effective as of May 23, 2024. She currently serves as the Company's Senior Vice President and Head of Programs & Portfolio Management.
瑞士楚格和波士頓，2024年5月23日（環球新聞專線）——專注於爲嚴重疾病開發變革性基因藥物的生物製藥公司CRISPR Therapeutics（納斯達克股票代碼：CRSP）今天宣佈任命醫學博士奈米什·帕特爾爲首席醫學官，自2024年5月28日起生效。帕特爾博士是一位經驗豐富的藥物開發人員，曾在廣泛的疾病領域工作，包括他最近擔任賽諾菲全球開發治療領域免疫學和炎症負責人的領導職務。此外，該公司還宣佈將工商管理碩士朱麗安·布魯諾晉升爲首席運營官，自2024年5月23日起生效。她目前擔任公司高級副總裁兼項目與投資組合管理主管。
譯文內容由第三人軟體翻譯。